J Pharm Pharmacogn Res 2(Suppl. 1): S40, 2014
Special supplement with the abstract book of LATINFARMA 2013
PL 005: PERSONALIZED CANCER VACCINES: WHO SHOULD PICK THE TARGET?
Overwijk WW.Houston, Texas, USA.
T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual’s cancer cells (the mutanome) encode unique peptides (mpeptides) that can be targets for T cells. The recent advances in nextgeneration sequencing and computation prediction allow, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about this extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. A major question is which peptides to target therapeutically. One approach is to select peptides based on mutation analysis and peptide binding prediction algorithms. Alternatively, we can let the immune system “pick” the target peptide by inducing a tumor microenvironment that promotes T cell priming in vivo. We will present data on both approaches and discuss pros and cons of either approach.